Albumin Level is Associated with Short-Term and Long-Term Outcomes in Sepsis Patients Admitted in the ICU: A Large Public Database Retrospective Research
DOI: https://doi.org/10.2147/CLEP.S396247
2023-03-04
Clinical Epidemiology
Abstract:Yan Cao, 1 Yingjie Su, 2 Cuirong Guo, 2 Liudang He, 2 Ning Ding 2 1 Department of Emergency Medicine, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan Province, People's Republic of China; 2 Department of Emergency Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan Province, People's Republic of China Correspondence: Ning Ding, Department of Emergency Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, No. 161 Shaoshan South Road, Changsha, Hunan, 410004, People's Republic of China, Tel +86731-8566-7935, Email ; Objective: This study aimed to explore the relationship between albumin level with short- and long-term outcomes in sepsis patients admitted in the intensive care unit (ICU) based on a large public database to provide clinical evidence for physicians to make individualized plans of albumin supplementation. Methods: Sepsis patients admitted in the ICU in MIMIC-IV were included. Different models were performed to investigate the relationships between albumin and mortalities of 28-day, 60-day, 180-day and 1-year. Smooth fitting curves were performed. Results: A total of 5357 sepsis patients were included. Mortalities of 28-day, 60-day, 180-day and 1-year were 29.29% (n = 1569), 33.92% (n = 1817), 36.70% (n = 1966) and 37.71% (n = 2020). In the fully adjusted model (adjusted for all potential confounders), with each 1g/dL increment in albumin level, the risk of mortality in 28-day, 60-day, 180-day and 1-year decreased by 39% (OR = 0.61, 95% CI: 0.54– 0.69), 34% (OR = 0.66, 95% CI: 0.59– 0.73), 33% (OR = 0.67, 95% CI: 0.60– 0.75), and 32% (OR = 0.68, 95% CI: 0.61– 0.76), respectively. The non-linear negative relationships between albumin and clinical outcomes were confirmed by smooth fitting curves. The turning point of albumin level was 2.6g/dL for short- and long-term clinical outcomes. When albumin level ≤ 2.6g/dL, with each 1g/dL increment in albumin level, the risk of mortality in 28-day, 60-day, 180-day and 1-year decreased by 59% (OR = 0.41, 95% CI: 0.32– 0.52), 62% (OR = 0.38, 95% CI: 0.30– 0.48), 65% (OR = 0.35, 95% CI: 0.28– 0.45), and 62% (OR = 0.38, 95% CI: 0.29– 0.48), respectively. Conclusion: Albumin level was associated with short- and long-term outcomes in sepsis. Albumin supplementation might be beneficial for septic patients with serum albumin< 2.6g/dL. Keywords: albumin, mortality, inflammation, sepsis, MIMIC-IV Albumin, as a significant protein and accounting for nearly one half of the total proteins in plasma, plays an important role in various physiological procedures. 1 Albumin not only regulates the acid–base balance and fluid distribution in the body, but also serves as a transporter of many substances including drugs and hormones. 2,3 Previous studies have explored the relationships between albumin level and clinical outcomes in many disorders including malignant tumor, 4 hepatic disease, 5 pancreatitis, 6 infectious disease 7 and even in COVID-19. 8 One study with 100,529 participants and a median follow-up of 8.5 years revealed that with each 1g/dl decrease in plasma albumin, the hazard ratios (HR) for ischemic heart disease, myocardial infarction and stroke were 1.17, 1.25 and 1.46, respectively. 9 Albumin also has been identified to have partly anti-inflammatory effects and be beneficial to the patients with sepsis. 10 In sepsis, a recent study showed that when admission serum albumin was ≤ 2.45 g/dL and the lowest serum albumin was ≤ 1.45 g/dL during hospitalization, the probability of survival in hospital declined by 70.6% and 76.4%, respectively. 11 However, few studies have investigated the effects of albumin level on long-term outcomes in sepsis and few definitive randomized controlled trials have been done to explore an outcome benefit of albumin supplementation in sepsis patients. Hence, we aimed to explore the relationship between albumin level with short- and long-term outcomes in sepsis based on a large public database to provide clinical evidence for physicians to make individualized plans for patients. Medical Information Mart for Intensive Care IV (MIMIC-IV) database ( https://mimic.mit.edu/iv/ ) is a large critical-care database that is an updated version of MIMIC-III. It covers more than 70,000 patients admitted in the intensive care unit (ICU) in a prolonged period time from 2008 to 2019 in Beth Israel Deaconess Medical Center of Boston and contains comprehensively clinical and laboratory data of patients. 12,13</ -Abstract Truncated-
public, environmental & occupational health